Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
In the SELECT trial, it reduced the risk of heart attack, stroke, and cardiovascular death by 20%, regardless of participants weight loss
Reduced GPx activity was also reported in HepG2 cells treated with a combination of fatty acids (Li et al
,
Again, similar to the results observed in mouse caSMCs, GLP-1(2836) activated PKA and conferred cytoprotection against oxidative stress injury in human caSMCs (Supplemental Figure 8, A and B)
Phase 3 Development and Current Evidence Level Retatrutide is in phase 3 development for several metabolic indications, including obesity and type 2 diabetes, while published phase 2 trials and 2026 phase 3 reports provide the main current human evidence [2], [7], [8]
Onset pattern: Published data indicates most GI events occurred during the dose-escalation phase and diminished over time as participants continued at stable doses
